Roche's CEA (carcinoembryonic antigen assay) products "breach Immunomedics' EU patent"
This article was originally published in Clinica
Executive Summary
An appeals court in the Netherlands ruled on June 27 that Roche's sale of carcinoembryonic antigen assay (CEA) kits in Europe infringe two European patents held by US company Immunomedics. CEA is one of the most widely used markers for colorectal and other cancers, said Morris Plains, New Jersey-based Immunomedics, as it welcomed the outcome of the latest round of patent infringement claims involving itself and Roche.